Medtronic conducted a post market clinical follow-up (pmcf) survey to seek out potential new risks and assess the performance of turbohawk and silverhawk peripheral plaque excision systems.Survey results received for an interventional cardiologist with 23 years¿ experience who was been using the silverhawk directional atherectomy system since 2007 and the and turbohawk since 2010.The physician has used a total of 350 turbohawk peripheral plaque excision systems with 49 of these being used in the past 12 months.The physician reported the device related complications of arterial dissection (treated accordingly), arterial perforation (treated with stent), arterial rupture (treated with stent), and embolism or arterial thrombosis (treated endovascularly with stent in embolectomy or angioplasty) during use of the device.None of these events were reported previously to medtronic.The physician all of the events to be not at all concerning.
|